Announcements Trials
Browse Landscape

Status

Recruiting 4Completed 4Active not recruiting 3Terminated 2Enrolling by invitation 1Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1

Interventions

3-Iodobenzylguanidine 4tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1fluorodopa F 18 1fluorocholine 1epigallocatechin gallate 1ensartinib 1dodecyl maltoside 1carbon-11 methionine 1burosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × brexucabtagene autoleucel × Clear all
NCT05776134 2026-04-08

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Gilead Sciences

Available
LymphoidOther hematologic neoplasm

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡